London, Ontario-based Front Line Medical Technologies, Inc. has received approval from Health Canada for its COBRA-OS™ (Control of Bleeding, Resuscitation, Arterial Occlusion System), an innovative medical device made to help more patients survive emergency situations.

This milestone for the former BURST venture comes after three years of research and development to create an easy-to-use aortic occlusion device with an extremely low-profile for temporary hemorrhage control and resuscitation. 

Approval of the COBRA-OS™ makes it the smallest REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) device on the market. This is significant in enabling health practitioners to deploy the device quicker and easier, resulting in decreased procedure times and the potential for improved patient outcomes.

“Even with all the advances in medicine today, trauma patients are primarily still dying from blood loss – this is our chance to change that,” said Adam Power, practicing vascular surgeon and co-founder of Front Line Medical Technologies. “While REBOA continues to emerge as a life-saving procedure, we saw the need for a simple, fast, low-profile device to maximize its benefit and ultimately save more lives.”

Made to be used in a variety of crisis situations, the device is being deployed in both hospital and pre-hospital conditions including military environments, while being investigated for nontraumatic cardiac arrest.

“When it comes to blood loss, timing is crucial and while most REBOA procedures take about 10 minutes, the COBRA-OS™ has taken just over a minute in our studies. Our ultimate goal is to lower the barriers to REBOA use around the world and after three years of hard work behind the scenes, Health Canada approval is our first step in making that happen.” For more information about Front Line Medical Technologies and to stay updated on the availability of the COBRA-OS™, please visit https://frontlinemedtech.com/.